| Document |
Document Title |
|
WO/2010/017563A1 |
Polymeric ionic liquids, methods of making and methods of using the same are disclosed.
|
|
WO/2010/012471A1 |
The present invention relates to salts of tramadol and ibuprofen, their crystal form, processes for preparation of the same and their uses as medicaments, more particularly for the treatment of pain.
|
|
WO/2010/013809A1 |
Provided are optically active titanium-salan compounds useful for asymmetric epoxidation and a process for efficient production thereof. In isolating an optically active titanium-salan compound useful for asymmetric epoxidation as a di-Î...
|
|
WO/2010/009508A1 |
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.
|
|
WO/2010/010412A2 |
The present invention is related to a method for the preparation of N-methyl-aryloxy-propanamine derivatives, which comprises reacting a suitable uretane derivative of the Formula (XXIV) with a Grignard reagent.
|
|
WO/2010/007253A2 |
A method for preparing the compounds of formula (IV): in which R1, R2, R3 and R4, which may be identical or different, are each a hydrogen atom, a linear or branched (C1-C6) alkyl group, a linear or branched (C1-C6) alkoxy group, a fluor...
|
|
WO/2010/004016A1 |
The invention relates to the use of compounds of the phenoxyalkylamine family of formula (I) in cosmetic and/or dermatological compositions, especially as preserving agents. The invention also relates to compositions comprising, especial...
|
|
WO/2010/000856A1 |
The present invention relates to a method for producing substituted aminobiphenylene, in particular 2-aminobiphenylene, and a method for producing (het)acrylic acid amides of such aminobiphenyenes, in particular 2-aminobiphenyene.
|
|
WO/2009/157418A1 |
Disclosed is a highly safe agent for treating and/or preventing diabetes or the like, which has excellent activity. Specifically disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (...
|
|
WO/2009/155488A2 |
The present invention relates to a novel salt and crystal of the Active Pharmaceutical Ingredient (API) O-Desmethylvenlafaxine, including methods of making the salt and crystal, pharmaceutical compositions comprising the salt and crystal...
|
|
WO/2009/147432A1 |
The present invention relates to an improved process for the preparation of rasagiline (1) 5 and its pharmaceutically acceptable salts. In particular it relates to a process for preparing rasagiline (1) and its salts substantially free f...
|
|
WO/2009/147141A2 |
The invention relates to functionalised diols of diamondoids wherein one of the two hydroxy groups is masked by a protective group, and to methods for producing said functionalised diols. The protective group is a -CHR1R2 group, wherein ...
|
|
WO/2009/147383A1 |
The present invention provides a process for preparing a compound of formula (Vl) or a salt thereof, the process comprising: (i) reacting 4-methoxyphenyl acetone with an amine of formula (VIII) under conditions of reductive amination to ...
|
|
WO/2009/147217A1 |
The present invention relates to compounds of formula (I) below in which: - R1 and R3 represent, independently of one another, a methoxy group optionally substituted by one or more fluorine atoms, - R2 and R4 represent, independently of ...
|
|
WO/2009/144517A1 |
The present invention relates to a process for the preparation of cyclohexanol derivatives of the general formula (I), wherein R stands for a hydrogen atom or a methyl group, in a one-step process from a cyano compound of the general for...
|
|
WO/2009/141170A2 |
The invention relates to a compound suited as entity carrier, having the general formula (I), wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier syst...
|
|
WO/2003/096987A9 |
|
|
WO/2009/133052A1 |
The present invention relates to a compound of formula (I), including any stereochemically isomeric form thereof, wherein the substituents are as defined in the specification and the claims; a N-oxide thereof, a pharmaceutically acceptab...
|
|
WO/2009/129938A1 |
The present invention relates to substituted phenoxybenzamide compounds of general formula (I) : in which R1, R2, R3, R4, R5, X, R6 and q are as defined in the claims, to methods of preparing said compounds, to pharmaceutical composition...
|
|
WO/2009/129395A1 |
Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.
|
|
WO/2009/129385A1 |
Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.
|
|
WO/2009/129387A2 |
Cationic lipids, cationic lipid based drug delivery systems, ways to make them and methods of treating diseases using them are disclosed.
|
|
WO/2009/125565A1 |
Disclosed is a novel ruthenium compound which is useful as an asymmetric reduction catalyst for a carbonyl compound. The ruthenium compound is represented by the following formula (I): Ru(X)2(Pxx)[R1R2C(NH2)-R3R4C(NH2)], and when the com...
|
|
WO/2009/121869A1 |
The present invention relates to a salt of a carboxylic acid with a diamine such as 2,2'-(ethylenedioxy)diethyl amine, 3,3'-(ethylenedioxy)dipropyl amine and 2,2'-oxybis(ethylamine) and a method of preparing such salts. Preferably the ca...
|
|
WO/2009/119858A1 |
Disclosed is a novel benzene compound which has an excellent immunosuppressing activity, an excellent rejection-inhibiting effect and others, and is reduced in adverse side effects including bradycardia. Specifically disclosed is a compo...
|
|
WO/2009/118474A1 |
The invention relates to a method for preparing a combretastatin (A): formula (I) in the form of a base or of an addition salt with an acid, which comprises coupling, in the presence of a base and of T3P, the salt of the (Z)-amino compou...
|
|
WO/2009/112461A1 |
This invention relates to novel triaryl derivatives derivatives, formula (I), a stereoisomer thereof or a mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, wherein all of X, Y and Z represent CH; or one or two ...
|
|
WO/2009/112703A1 |
Esters derived from 2-amino-2-phenylalkanol of general formula (I) in which: R1 is H, straight or branched C1 to C4 alkyl, straight or branched C2 to C4 alkyl substituted by OH, alkoxy, alkylthio, acyloxy, NH2, alkylamino, dialkylamino, ...
|
|
WO/2009/106386A1 |
The invention relates to a process for preparing optically active α-aminoacetals by resolution of a racemic mixture or of a mixture of enantiomers via the formation of diastereoisomeric salts, and also novel intermediates in the form of...
|
|
WO/2009/090669A2 |
A novel process for the selective reduction of halonitroarenes in general and halonitroaromatic arenes in particular, without the hydrogenolysis of the C-Cl (where, X represents F-, Cl-, Br- and I) and the C-O-C bonds, in the presence of...
|
|
WO/2009/089680A1 |
Provided herein are methods of modulating membrane potential of a cell membrane using self-assembling compounds. Also provided herein are methods of regulating a natural voltage-dependent ion channel in a cell membrane using the self-ass...
|
|
WO/2009/080655A1 |
The present invention relates to a process for the preparation of phenethyl tertiary amine derivatives by hydrogenation of phenylacetonitriles. More particularly, the present invention relates to a one pot two step process for the prepar...
|
|
WO/2009/068177A1 |
The present invention provides a compound of formula (I): wherein: • R1 is a group selected from -CH2OH,-NH(CO)H and • R2 is a hydrogen atom; or • R1 together with R2 form the group -NH-C(O)-CH=CH-, wherein the nitrogen atom is bou...
|
|
WO/2009/067597A1 |
Compounds of the formula: (I) are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.
|
|
WO/2009/065406A2 |
The invention relates to novel cyclic hydrocarbon compounds and derivatives thereof, processes for the preparation thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions c...
|
|
WO/2009/062377A1 |
A method of resolution of an important chemical intermediate, 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, comprises the following steps: reacted its two enantiomers of 4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane with d...
|
|
WO/2009/060282A2 |
Described are novel compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, an...
|
|
WO/2009/055869A1 |
The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion pass...
|
|
WO/2009/054916A2 |
The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.
|
|
WO/2009/052078A1 |
The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compou...
|
|
WO/2009/048527A1 |
The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention als...
|
|
WO/2009/043117A1 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
|
WO/2009/041000A1 |
The object is to provide an aliphatic amine alkylene oxide adduct which shows a good color when used as a detergent, and which has a sufficiently sharp molecular weight distribution, high purity, and a low odor. Thus, disclosed is an ali...
|
|
WO/2009/042013A1 |
The present invention provides processes and synthetic intermediates for the synthesis of 4-substituted ((1S, 2S, 4R)-2-hydroxy-4-{7H-pyrrolo[2/3-d]pyrimidin-7- yl}cyclopentyl)methyl sulfamates, which are El activating enzyme inhibitors,...
|
|
WO/2009/034432A2 |
The invention relates to compounds of formula: (I) processes and intermediates for their preparation, their use as muscarinic antagonists and pharmaceutical compositions containing them.
|
|
WO/2009/035020A1 |
Disclosed is a compound represented by the formula (I) below as a dihydronaphthalene compound having a chemical structure which is excellent in production efficiency when compared with lasofoxifene and nafoxidine. This compound is useful...
|
|
WO/2009/023964A1 |
The present invention relates to biphenyl compounds of formula (I). These compounds are renin inhibitors of a non- peptidic nature and of low molecular weight. The invention further relates to a pharmaceutical composition containing said...
|
|
WO/2009/020910A1 |
A compound of formula (I): wherein k is 1 or 2; Y is -CH2CH(CF3)2 or -(CH2)nCF; X is hydrogen, -(CH2)nRf, or -C(O)[CF(A)]P-B-Rf> wherein B is a divalent radical selected from the group consisting of a covalent bond, -O- and -(CH2)m-; A i...
|
|
WO/2009/018959A1 |
The present invention concerns salts of Tramadol and Naproxen, especially the (R,R)-tramadol-(S)-naproxene salt, their crystalline form of as well as their process for preparation and their uses as medicaments, more particularly for the ...
|
|
WO/2009/018169A1 |
Disclosed herein are substituted cyclohexanol opioid receptor modulators and/or neurotransmitter reuptake modulators of Formula I or Formula II, process of preparation thereof, pharmaceutical compositions thereof, and methods of use ther...
|
